BioMelbourne Network Progressing BioIndustry

16th-19th November. The Australian Health & Medical Research Congress.
The theme is 'Transdisciplinary Approaches to Chronic Diseases'. More

Victorian BioPortal

Looking for Something?

The Victorian BioPortal is the largest online search engine for biotechnology in Victorian with over 2,000 individual listings.

Start your search now

BioMelbourne Network

The Building Global Bridges program provides grants of between $100,000 & $500,000 to Victorian life science companies to develop partnerships with Massachusetts companies in late stage life sciences R&D projects. The program helps Victorian innovation to accelerate, access expertise, develop skills & better reach global markets and international investors. Applications close 17 September 2013.

Building Global Bridges

Australia’s medical research community unites to champion the Medical Research Future Fund

16th September - New campaign launches in Melbourne today. Australians are being urged to imagine a healthier future as the Medical Research Future Fund (MRFF) Action Group launches its campaign in support of enhanced public investment in health and medical research. Medical research advances national prosperity and wellbeing and it does this by making individual lives better and more product... read more…

Nexvet Expands Australian Veterinary Biologics Research Centre

15th September - Veterinary biologic therapy developer Nexvet Biopharma today announced that Dr. Samantha Busfield, PhD, and Dr. Dallas Hartman, PhD, two senior biopharmaceutical research and development executives, have joined Nexvet’s veterinary biologics research centre in Melbourne, Australia.  This facility is designed to support Nexvet’s existing programs in companion animal therapies, an... read more…

Global Kinetics Corporation Secures FDA Clearance to Sell Parkinson’s KinetiGraph™ in USA

11 September 2014.  Australian technology company Global Kinetics Corporation has achieved a key milestone, securing important US regulatory approval to market their world leading Parkinson’s disease mobile health technology in the high value American market.Announcing the Food and Drug Administration decision, GKC Managing Director Mr Andrew Maxwell said the company was now moving swiftly to e... read more…

Victorian Government Grants Help Businesses Rise to New Challenges

10 September 2014.  Victorian Minister for Innovation, Louise Asher, announced that 11 grants of $75,000 each have been awarded to 10 innovative Victorian businesses under Round 1 of the Victorian Government’s Driving Business Innovation program. Funded in the 2013 State Budget, the $16 million Driving Business Innovation program provides financial support for small to medium enterprises (SMEs)... read more…

New round of Victorian Postdoctoral Research Fellowships

9 September 2014.  Applications are now open for the second round of the Napthine Government’s prestigious $1.8 million Victorian Postdoctoral Research Fellowships Program.The Minister for Innovation, Louise Asher said the fellowships, which honour a 2010 election commitment, are strengthening Victoria’s innovation capabilities by enabling talented young researchers to work at world leading res... read more…

Government Plan to Help Business Innovation

9 September 2014.  Businesses will get government help to invent and commercialise new products and enter global markets under a plan to be released within weeks.But Industry Minister Ian Macfarlane says it won't be a case of "picking winners", nor will it be a return to "endless cash programs and handouts".For the past year, Mr Macfarlane has been working with industry, researchers and trainer... read more…

tinAway, a potential cure for chronic tinnitus: a crowdfunding campaign is launched to fund a clinical trial

2nd September - tinAway is an mHealth app being developed as a potential cure for chronic tinnitus A crowdfunding campaign has been launched on September 1, 2014, to support a clinical trial of the tinAway iPad app in chronic tinnitus A novel treatment that may provide a cure for chronic tinnitus is seeking support for development costs through a crowdfunding campaign. The campaign is no... read more…

Professor Chubb Releases “Science, Technology, Engineering and Mathematics: Australia's Future”

2 September 2014.  Professor Chubb released his recommendations for a strategic approach to science and its related fields. The document can be downloaded here “Science, Technology, Engineering and Mathematics: Australia’s Future outlines what we need to do to build a stronger, more competitive Australia,” Professor Chubb said at Parliament House. “Science is infrastructure and it is critica... read more…

More To Report From Australian Life Sciences -- And Some Best Practices From The BioMelbourne Network

2nd September - Former CEO of BioMelbourne Network, Michelle Gallaher spoke with Louis Garfuilo, Executive Director, Outsourced Pharma. It was again named one of the “happiest countries” in the world by the OECD. Scientific American Worldview ranked it fourth in 2014 in the global biotech industry, a one-year vault from seventh. For the fourth year in a row, the Economic Intelligence Unit annu... read more…

Australia’s medical research sector backs the Medical Research Future Fund

1st September - New MRFF Action Group advocates for the most important initiative in Australian medical research in generations.The organisations that carry out Australia’s world-leading medical research have joined forces to support the Federal Government’s proposed Medical Research Future Fund (MRFF). The MRFF Action Group – which comprises members from organisations representing all of Aust... read more…

Bioscience Managers Capital Return on Healthcare Fund I Locks in 24.7% IRR for Investors

28 August 2014.  Leading Australian healthcare fund manager Bioscience Managers has maintained its exceptional performance by returning capital to investors from its Australian Bioscience Fund I at 24.7% annual IRR. Since the first commitments in July 2008 the fund has called $35 million to end with $56 million returned to investors.  This corresponds to a closing unit price of $1.76 for each d... read more…

Phosphagenics Completes First IND Enabling Study for TPM®/Oxymorphone Patch

28 August 2014.  Australian drug delivery company, Phosphagenics Limited (the Company) (ASX: POH, OTCQX: PPGNY),announces that the first of its additional studies designed to further characterise the TPM®/Oxymorphone patch, in support of an Investigational New Drug (IND) application with the FDA has been completed.  The study was conducted on 15 healthy volunteers at Linear Clinical Research’s ... read more…

Pharmaceutical Executive Joins Mesoblast as Chief Financial Officer

25 August 2014 - Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the appointment of pharmaceutical executive Mr Paul Hodgkinson as Mesoblast Chief Financial Officer. Mr Hodgkinson has broad and high-level international pharmaceutical experience in allaspects of finance, strategic planning, business development and licensing,manufacturing and supply chain, and procurement. From 2011 ... read more…

BioMelbourne Network Submission - Senate Standing Committee on Economics - Inquiry into Australia’s Innovation System

31st July, 2014 - BioMelbourne Network has lodged the following submission - http://www.aph.gov.au/DocumentStore.ashx?id=92ba39b5-69b6-4dd9-a4a5-8a8ad9a9de64&subId=298526 Contact;Dr Krystal EvansChief Executive OfficerBioMelbourne Network E: kjevans@Biomelbourne.orgM: 0435 622 934 read more…

IDT Executes Binding Memorandum of Understanding with Mayne Pharma for Exclusive Distribution of Temozolomide in the US

29th July, 2014 - IDT has now secured US distribution for its generic Temozolomide product on favourable commercial terms. IDT  Australia  Limited  (ASX:IDT)  is  pleased  to  announce  that  it  has entered  into  a  binding  Memorandum  of  Understanding  (MOU)  with  Mayne  Pharma’s  US Products  division  to  distribute  IDT’s  generic  Temozolomide  product  in  the  United  States  of Am... read more…

Collaboration announced to advance malaria vaccine development

29th July, 2014 - Burnet Institute and ARTES Biotechnology have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI).The project will use exciting novel technology developed at Burnet Institute by Deputy Director, Associate Professor David Anderson and colleagues. ARTES holds the international patent rights and adapted the platf... read more…

Phosphagenics Opioid Patch Program Update

28th July, 2014 - • Next phase of the TPM®/Oxymorphone clinical development program has commenced• TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4/2014• TPM®/Oxymorphone Phase 2 trial to be conducted in the United States in H1/2015 Australian drug delivery company, Phosphagenics Limited (“the Company”) (ASX: POH, OTCQX: PPGNY), provides the following update on its opioid t... read more…

Business Council of Australi (BCA) - Actions Needed to Build Australia’s Comparative Advantages

28th July, 2014 - Continuing Australia’s remarkable run of economic growth will require businesses and governments to take more deliberate and purposeful steps in response to global forces of change, Business Council of Australia President Catherine Livingstone said today. Ms Livingstone used her first major speech as BCA President to launch a landmark paper that recommends a radical rethink o... read more…

Dr who? Campaign to boost digital profile of Australia's female scientists

27th July, 2014 - Ever heard of Dora Lush? She was an Australian microbiologist working in the 1940s on developing a vaccine for a deadly disease known as scrub typhus. She accidentally pricked her finger with a contaminated needle. Three weeks later, she died from the very disease she was trying to tame. Hailed as a martyr for science by her contemporaries, she kept donating blood samples fro... read more…

Acrux Appoints New CEO

25th July, 2014 - Acrux (ASX: ACR) today announced the appointment of a new Chief Executive Officer and Managing Director, Mr. Michael Kotsanis. Michael is currently Chief Commercial Officer of Synthon Holding BV in the Netherlands. He has 25 years’ experience in the global pharmaceutical industry, beginning his career with Boehringer Ingelheim before moving to F. H. Faulding (which was acquire... read more…